Pasireotide

Size	Price	Stock	Quantity
Get Quotation Now Add to Cart Bulk Inquiry

Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.

Chemical Information

Product name：Pasireotide	Purity：98% min
CAS NO：396091-73-9	Solubility：
Molecular Formula：C₅₈H₆₆N₁₀O₉	Package：Package according to customer requirements
Molecular Weight：1047.21	Storage：-20ºC

Quality control

Remarks

Pasireotide, also known as SOM230, is an orphan drug approved for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Related Prodcuts:

Icatibant; Lanreotide; Nesiritide; Leuprolide Acetate; Liraglutide; Lypressin; Atosiban; Oxytocin; Bivalirudin; Pramlintide Acetate; Calcitonin Salmon; Alarelin Acetate; Sincalide; Somatostatin Acetate; Glucagon HCl

References

1: Silverstein JM. Hyperglycemia induced by pasireotide in patients with Cushing's disease or acromegaly. Pituitary. 2016 Oct;19(5):536-43. doi: 10.1007/s11102-016-0734-1. Review. PubMed PMID: 27405306.

2: Pasireotide (Signifor): Treatment of Adult Patients with Cushing Disease [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug. Available from http://www.ncbi.nlm.nih.gov/books/NBK349174/ PubMed PMID: 26962592.